Effects of sclerostin antibody on bone healing  

作　　者：Atsushi Mihara Kiminori Yukata Toshihiro Seki Ryuta Iwanaga Norihiro Nishida Kenzo Fujii Yuji Nagao Takashi Sakai 

机构地区：[1]Department of Orthopedic Surgery,Yamaguchi University Graduate School of Medicine,Ube 755-8505,Japan

出　　处：《World Journal of Orthopedics》2021年第9期651-659,共9页世界骨科杂志（英文版）

摘　　要：Promoting bone healing after a fracture has been a frequent subject of research.Recently,sclerostin antibody(Scl-Ab)has been introduced as a new anabolic agent for the treatment of osteoporosis.Scl-Ab activates the canonical Wnt(cWnt)-β-catenin pathway,leading to an increase in bone formation and decrease in bone resorption.Because of its rich osteogenic effects,preclinically,Scl-Ab has shown positive effects on bone healing in rodent models;researchers have reported an increase in bone mass,mechanical strength,histological bone formation,total mineralized callus volume,bone mineral density,neovascularization,proliferating cell nuclear antigen score,and bone morphogenic protein expression at the fracture site after Scl-Ab administration.In addition,in a rat critical-size femoral-defect model,the Scl-Ab-treated group demonstrated a higher bone healing rate.On the other hand,two clinical reports have researched Scl-Ab in bone healing and failed to show positive effects in the femur and tibia.This review discusses why Scl-Ab appears to be effective in animal models of fracture healing and not in clinical cases.

关 键 词：Canonical Wnt-β-catenin pathway Fracture healing OSTEOPOROSIS Romosozumab Sclerostin antibody 

分 类 号：R683[医药卫生—骨科学]